This review describes a comprehensive investigation focusing on syntheses of analytical reagents, followed by their utilization in development of analytical methods, and leading to practical applications for rational use of medicaments centeringonabuseddrugs.Manykindsofanalyticalreagentsforfluorescenceandchemiluminescencedetectionshave beensynthesizedwiththeintentionofimprovingsensitivity.Byproperlycombiningthedevelopedanalyticalreagents with an HPLC separation technique, one could determine ultra-small amounts of abused drugs such as stimulants, narcotics and obesity drugs in various matrices. Furthermore, chiral analyses of some abused drugs and evaluation of theirpotentialfordrug-druginteractionwerealsoperformed.Thedevelopedmethodsmightbeusefulforforensicand toxicologicalstudiesondrugabuse.Also,theresultsobtainedinourstudymightcontributetothepredictionofandthe protectionofhumanhealthfromrisksofabuseddrugs.
Introduction
Medicaments, which are biologically active as internal physiologically active compounds, have been contributing to humanhealth.However,theyhavesometimesshowedaserious riskforhumanhealth,andthusthepromotionofrationaluseof medicamentsisveryimportant.Developmentsofpracticaland precise analytical methods for medicaments could be the first stepstoleadtosuchrationaluse.Todate,numerousanalytical methods for medicaments have been developed by using gas chromatography (GC), GC-mass spectrometry (GC-MS), highperformance liquid chromatography (HPLC) and capillary electrophoresis (CE) as summarized in the reviews. 1,2 GC has beencommonlyusedfortheanalysisofvolatilecompounds,but itcannotbeappliedtonon-volatilecompounds.AlthoughGC-MS is sensitive and has been predominantly used in forensic sciences to determine medicaments such as abused drugs, it requires an expensive experimental apparatus. On the other hand, HPLC shows excellent capability for the analysis of aqueoussamples.Mostmedicamentsinbiologicalsamplesare commonly non-volatile polar compounds, and thus HPLC is moresuitablethanGCfortheiranalysis.InHPLCanalysis,the choice of detection method is important and many kinds of detectors have been used in various cases. For the sensitive determination of medicaments, fluorescence (FL), chemiluminescence (CL) or MS detections have been adopted. Among these, an HPLC-FL method has been extensively employedfordeterminationoftraceamountsofcompoundsdue to its high sensitivity and selectivity. Furthermore, its instruments are inexpensive compared to those for MS (or MS/MS) detection. CL is the emission of light from the electronically excited luminophores by a chemical reaction of precursors of those species. The CL reaction requires no excitinglightsource.Andthus,thispermitsanincreaseinthe detector'ssensitivityandanattainmentofalargesignal-to-noise (S/N) ratio, resulting in a lower limit of detection (LOD). Therefore, several CL methods are of growing importance in forensic, pharmaceutical and biomedical analyses. Among them, peroxyoxalate chemiluminescence (PO-CL) has been found to be one of the most effective CL methods for determinationofultra-smallamountsoffluorophores.InaPOCLsystem,oxalatesoroxamidesreactwithhydrogenperoxide inthepresenceofafluorophoretoproduceanemissionoflight. The reaction is achieved by a chemically initiated electron exchangeluminescence(CIEEL)mechanismviaahighenergy intermediate which forms a charge transfer complex with the co-existing fluorophore. The electron is transferred to the fluorophore, which transits to an excited state and returns to a ground state by emitting a photon (hv) (Fig. 1) . 3 Hydrogen peroxide most effectively gives CL emission as an oxidant in PO-CLsystems.
Furthermore, labeling is one of the powerful techniques to expand adaptation of the methods with FL and CL detections. For medicaments having no fluorescent property, a labeling is recommendedinordertointroducedesirablecharacteristicsinto the molecule. A labeling reaction is commonly achieved by a selective reaction between the functional group of the analyte and that of the labeling reagent. Labeling serves to improve sensitivity, selectivity and the chromatographic behavior. Therefore,manylabelingreagentshavebeendevelopedforeach reactivefunctionalgroup.Todate,manyreviewsdescribingthe labelingreagentsforHPLChavebeenpublished. [4] [5] [6] [7] [8] Amongmedicaments,manykindsofdrugshavebeenwidely abused and such abuse has caused serious social problems worldwide. For instance, methamphetamine (MP) is the most popular abused drug in Japan. In addition to MP, illegal designerdrugs:3,4-methylenedioxymethamphetamine(MDMA) and 3,4-methylenedioxyamphetamine (MDA), have recently becomepopularandtheirusehasspreadamongyoungpeople. 9 On the other hand, obesity drugs such as fenfluramine (Fen), phentermine (Phen), N-nitrosofenfluramine (N-Fen), mazindol (Maz) and phenylpropanolamine (PPA) were adulterated in commercially available diet products and have caused serious side effects. 10 Because of the growing seriousness of these situations,thepredictionofandtheprotectionofhumanhealth fromtherisksofabuseddrugarerequired.Forthesepurposes, development of a sensitive and selective analytical method of drugsthatmaybeabusedisessential.
The aim of this review is to overview our recent studies on sensitive HPLC methods for determination of medicaments centeredondrugsthatmaybeabused.Thisreviewconsistsof three parts: 1) synthesis of original fluorescence and chemiluminescence reagents including their applications; 2) development of analytical methods for abusable drugs; and 3) practicalapplicationsofthedevelopedmethods.
Somesensitivedetectionmethodsofabusabledrugsinvarious matrices by HPLC-FL and -PO-CL methods are presented. Furthermore,theirpracticalapplicationsforchiralanalysisand evaluationofpharmacokineticdrug-druginteractionscausedby some abusable drugs will be described. In each section, representative interesting results from our recent publications aresummarized.
Synthesis and Evaluation of Fluorescence and Chemiluminescence Reagents with Their Applications
For development of analytical methods of medicaments, a choiceofanalyticalreagentisveryimportant,sinceitaffectsthe following experiments. The design and synthesis of original analyticalreagentsincompliancewiththepurposesofanalysis arethefirststeptopromoteanalyticalsuccess.Inthissection, syntheses of analytical reagents for FL labeling and their applicationstoFLandPO-CLdetectionsaredescribed.
2·1 Bezoxadiazole derivatives
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Among the various fluorescence labeling reagents, bezoxadiazole derivatives have desirable properties as an FL labeling reagent, because the labeling reagent has no fluorescence itself and the labeled compounds give an intense fluorescence at a longer wavelength region to compounds in biological sample. We synthesized several benzoxadiazole labeling reagents as shown in Fig. 2 . 4-(N,NDimethylaminosulfonyl)-7-hydrazino-2,1,3-benzoxadiazole (DBD-H), 4-aminosulfonyl-7-hydrazino-2,1,3-benzoxadiazole and4-hydrazino-7-nitro-2,1,3-benzoxadiazolehydrazine(NBD-H·NH2NH2)weresynthesizedforaldehydesandketones. 11 The labeledcompoundsfluorescedatwavelengthsfrom548to580 nmwithexcitationsfrom450to470nm.Amongthem,DBD-H was highly sensitive for short-chain aliphatic aldehydes with a sub-pmollevelofLODforanHPLC-FLmethod. 12 Thisreagent could be applied to monitor the acetaldehyde level in normal humanplasmaafteraningestionofethanol.Furthermore,DBD moietywasfoundtobeefficientlyexcitedbyPO-CLreaction. 13 Based on this fact, medroxyprogesterone acetate, 14 long-chain aliphaticaldehydes 15 TheDBD-labels ofaminoacidsfluoresceat505nmwithexcitationat385nm. ByusingDBD-NCS,anovelanalyticalmethodforaminoacid sequenceandconfigurationdeterminationofpeptidecontaining D-orL-aminoacidscouldbesuccessfullydeveloped. 18 A DBD-type of labeling reagent, 4-(N,Ndimethylaminosulfonyl)-7-fluoro-2,1,3-benzoxadiazole (DBD-F), reacts with amino acids and biogenic amines; the resultant labels could be sensitively detected by PO-CL detection. The instrumental limit of detection (2 fmol) of authentic DBDproline was comparable to that (1.3 fmol) of authentic dansylproline by the HPLC-PO-CL method. 13 b-Blockers having an isopropylamino group including alprenolol, metoprolol, oxprenololorpropranololweredetectedwithafewfmollevels ofLOD. 19 Moreover,ebiratide,oneofthesyntheticanalogues of ACTH4-9 for Alzheimer disease could also be determined anditstimecourseinratplasmacouldbetracedwiththelower levelsofsub-pmol/mL. 20, 21 2·2 Lophine derivatives [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] Lophine derivatives are well-known potential fluorescent or chemiluminescent compounds. Therefore, a variety of lophine derivativesweresynthesizedasshowninFig.4andtheirFLand CL properties were evaluated. The lophine derivatives substituted by OCH3 at the 3-and 4-positions (compound 17), and COOH (7), COCl (8), CONHNH2 (9) and CONHNHCO(CH2)4CH3(2)atthe4-positiononthephenylring at the 2-position of imidazole skeleton showed strong chemiluminescenceintensitieswhichwerecomparabletothatof lophineitself.
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In2-substituted-4,5-di(2-pyridyl)imidazoles,2-substituted-4,5-di(2-furyl)imidazoles and 2-substituted-4(or 5)-(4-dimethylaminophenyl)-5(or 4)-phenylimidazoles, the 2-furyl groups showed intense fluorescence, while those having 2-pyridyl group gave weak intensities. 23 The relative chemiluminescence intensity (RCI) of 4-[4(or 5)-(4-dimethylaminophenyl)-5(or4)phenyl-1H-imidazole-2-yl]benzoylchloride obtainedbyaflowinjectionanalysis(FIA)methodshowedthe largest RCI, corresponding to 40% of that of lophine. Among them, 2-(4-hydrazinocarbonylphenyl)-4,5-diphenylimidazole (HCPI, compound 9) and 4-(4,5-diphenyl-1H-imidazol-2-yl)benzoyl chloride (DIB-Cl, compound 8) were found to be availableasfluorescencelabelingreagents.
HCPI reacts with fatty acids to give intensely fluorescent labels at room temperature by using condensing reagents, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (ECD) and pyridine. When HCPI was used, 7 kinds of free fatty acids includingmedium-andlong-chainsaturatedfattyacids(C6,C10, C12, C14, C16, C18 and C20) could be determined with margaric acid(C17)asaninternalstandard(IS),asshowninFig.5.The LODs were 7 -56 fmol (S/N = 3). 24 Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are major long-chain n-3polyunsaturatedfattyacidswhichareabundantlypresentin fish oils. The labeling of these compounds with HCPI was performed in 20 min at room temperature in the presence of ECD and pyridine. 25 EPA and DHA in human serum, dietary supplementsandpharmaceuticalpreparationsweresuccessfully determined with LODs of 200 fmol (S/N = 3). Free carnitine and short-and medium-chain acylcarnitines in human plasma could be determined by HPLC with HCPI under the mild labelingconditions.Thismayhavetheadvantageofpreventing racemizationduringthelabelingofenantiomersofcarnitineand acylcarnitines. 26 Furthermore,HCPIwasalsoachemiluminogenic labeling reagent, and could be used for PO-CL detection of saturatedfreefattyacids(C16andC18). 27 DIB-Cl is one of the useful labeling reagents because it exhibits high sensitivity for amines and phenolic compounds. Thisreagentrapidlyreactswithaminesorphenoliccompounds inthepresenceofabasiccatalystorunderanalkalinecondition. For instance, urinary phenol, cresols and xylenols could be determined by an HPLC-FL method. 28, 29 Bisphenol A (BPA), which has attracted considerable attention owing to its endocrine-disrupting effect, was labeled with DIB-Cl and determinedinvariedbiologicalmatrices.BPAthatmigratedfrom polycarbonatebabybottleswasdeterminedbyanHPLC-PO-CL method. 30 Also,simultaneousdeterminationofBPA,bisphenol B,bisphenolE,bisphenolFand4-nonylphenolfrompolyvinyl chlorideplasticsweredemonstratedbyanHPLC-FLmethod. 31 Moreover,labeledBPAwithDIB-Clinbiologicalfluidssuchas plasma, 32 microdialysates 33 and ascetic fluid 34 could be determinedbyanHPLC-FLmethod.Theresultsobtainedfrom thesestudiesclarifiedthepenetratingpropertyofBPAthrough the blood-brain barrier 33 and the relationship of BPA concentrationsinserumsamplesandinasceticfluidsamples.
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2·3 Reagents for PO-CL detection 35-42
For PO-CL detection, the choice of an oxalate and a fluorophoreisoneofthemostimportantfactorstoimproveCL intensity.Severalaryloxalatesandfluorophoreswereoriginally synthesized to increase the sensitivity of PO-CL detection. Representative aryl oxalates such as TCPO, bis(2,4-dinitrophenyl)oxalate (DNPO) and bis[2-(3,6,9-trioxadecyloxycarbonyl)-4-nitrophenyl]oxalate (TDPO) have been used in a PO-CL detection system. However,TCPO and DNPOshowlowsolubilityinacetonitrileandacetonewhichare common solvents for postcolumn CL reagents in HPLC. Improvingthesolubilityofoxalatesinthesesolventsisdesirable for preparing proper concentrations of reagent solutions to produceanemissionoflight.Forthisaim,eightnoveloxalates having an alkoxy moiety as well as TDPO, which shows high solubilityonacetonitrileandacetone,weresynthesized. 35 Imai et al. reported that 2,6-bis(diethanolamino)-4,8-dipiperidinopyrimido [5,4-d] pyrimidine (dipyridamole) showed the highest RCI in a study on estimation of sensitivity of fluorescent compounds by the PO-CL reaction system. 36 As shown in Fig. 6 , pyrimido [5,4-d] pyrimidine derivatives (compounds 39 -57) synthesized could be anticipated to be usefulfluorophoresforPO-CL. 37 Evaluationsofthederivatives asaPO-CLreagentbyFIAandbatchmethodswereperformed, and the combinations of TCPO and 2,4,6,8-tetrathiomorpholinopyrimido [5,4-d] pyrimidine (compound 47, TMP)gavemorethan10timeslargerRCIcomparedtothoseof representativefluorophoressuchas9-aminoacridine,fluorescein, rhodamine B, 9,10-diphenylanthracene and perylene. 38, 39 By using this combination, sensitive determination of hydrogen peroxide was achieved with an LOD of 10 nM at a signal-toblank ratio of 3. 40 Furthermore, substrates for oxidase such as glucose, uric acid, 41 mono-acetyl polyamines and polyamines 42 could be determined. The method was based on the enzyme reaction to generate hydrogen peroxide, which was performed on-lineusinganimmobilizedenzymecolumnreactor.Atypical chromatogramofthestandardpolyaminesisshowninFig.7.
Development of Analytical Methods for Drugs of Abuse
Analysisofabusabledrugsinforensicstudyincludingcriminal justice requires sensitivity, selectivity and reliability. Also, a rapid and simple method is needed in clinical chemistry includingemergencytreatment.Therefore,forthedevelopment ChromatogramoftheHCPI-fattyacidderivatives.A100-ml portion of a standard mixture of fatty acids (5 nmol/ml each) was treated according to the experimental procedure. Peaks: 1, 4, 6, 7, reagentblank;2,C5;3,C6;5,C8;8,C10;9,C12;10,C14;11,C16;12, C17(I.S.);13,C18and14,C20.PrintedfromRef.24withpermission fromElsevierSciencePublishersB.V. of a new analytical method of such drugs, sophisticated analyticaltechniquesmustbeused.Inourstudies,thecombination of labeling technique using original reagents described in the above section and an HPLC method could provide the highly sensitive and selective determination of such drugs. In Fig. 8 , theabusabledrugsexaminedinourstudyarelisted.
3·1 Stimulants 43-51
Development of a sensitive and selective determination method of stimulants (MP and amphetamine (AP)) has been attractingconsiderableattentionbecauseoneofthese,MP,isthe mostwidelyabuseddruginJapan. 9 Sincestimulantsandtheir related compounds have reactive functional groups such as primary or secondary amino groups, a labeling reagent of amines for sensitive determination could be applied with an HPLC-FLoraPO-CLdetectionmethod.Inourreports,various labelingreagentssuchasfluoresceinisothiocyanate, 43 4-fluoro-7-nitro-2,1,3-benzoxadiazole 44, 45 and DIB-Cl [46] [47] [48] [49] for FL detectionandDBD-F 50 andN-(4-aminobutyl)-N-ehylisoluminol 51 for PO-CL detection were examined. Especially, DIB-Cl was one of the most useful FL labeling reagents for MP and its relatedcompoundsowingtoitshighsensitivityandreactivityto amines. MP, AP, p-hydroxylmethamphetamine (p-HMP), phydroxyamphetamine (p-HAP) and ephedrine (EP) in human urine were determined with a simple solid-phase extraction (SPE). 46 The labeling reaction of DIB-Cl with amines easily proceededatroomtemperatureinthepresenceoftriethylamine. The sensitivity of the proposed method with LOD of 0.6 -5.2 fmol(S/N=3)washigherthanthatofDns-Cl.Usingverysmall amountsofurine(about10mL),MPanditsrelatedcompounds could be determined. The method was successfully applied to theurinesamplescollectedfromMPaddicts.AP,p-HMPand p-HAP, which are major metabolite of MP, are simultaneously determined in addition to MP by this method. This result indicates the proposed method might be useful in forensic, pharmacokineticandtoxicologicstudies.
Analysis of abusable drugs in blood and hair samples is important in forensic or clinical studies. However, its achievementmaybemoredifficultcomparedtourineanalysis, becausetheconcentrationsofanalytesinmatricesandthesizes of the usable sample are sometimes limited. When these limitationswereovercome,thedeterminationofMPandAPin human plasma and hair samples by an HPLC-FL method with Fig. 7 Chromatograms of the standard polyamines. Sample: putrescine (Put), acetyl putrescine (AcPut), 250 pmol/injection; cadaverine (Cad), acetyl cadaverine (AcCad), spermidine (Spd), N1-acetylspermidine(N1-AcSpd)andN8-acetylspermidine(N8-AcSpd), 500pmol/injection.Peaks:1,AcPut;2,AcCad;3,Put;4,Cad;5,N1-AcSpd;6,N8-AcSpd;7,Spd.Thearrowindicatesthechangingofthe eluents.Sensitivity:5.0nAFS.OtherHPLCconditionsareasinthe Experimental.PrintedfromRef.42withpermissionfromTheJapan SocietyforAnalyticalChemistry. Fig. 8 Chemicalstructuresofabuseddrugsexamined.
26 ANALYTICALSCIENCESJANUARY2009,VOL.25 DIB-Clcouldbeperformed. 47 Thesamplesizesusedforplasma andhairwere100mLand1mg,respectively.Asanapplication, MP and AP in plasma and hair obtained from two cases of illegallyingestedMPweredetermined.Oneoftheadvantages ofhairanalysisistoobtainhistoricalinformationoftheabuser by segmental analysis. However, an investigator encounters greatdifficultytousethemethodsuccessfully,becausegenerally atraceamountofanalytesisincludedinasmallsizeofsample. AnHPLCmethodwithFLdetectionofMPandAPlabeledwith DIB-Cl was developed due to its excellent sensitivity and reactivity. 48 Abusers' hair cut into 1 cm long segments of 10 strandsofhairwasusedforanalysis.Sixhairsamplesobtained fromabusersweresegmentallyanalyzedandtheconcentrations of MP determined in each segment were in the range of 1.8 -170.7ng/mghair.Furthermore,uniquesamplessuchaspartsof thegarmentsofabuserswereusedfordeterminationofMPand AP by an HPLC-FL method. 49 The analytes were completely extractedfromtextilewithamixtureofchloroformandpropan-2-ol. The LOD of MP was 0.4 pg (S/N = 3). Typical chromatogramsobtainedbytheproposedmethodareshownin Fig. 9 . Contents of MP and AP were higher in underwear comparedtopantsbecausetheformermightmoreeasilycontact withskin.ThisresultsupportstheideathatMPandAPcanbe excretedthroughperspiration.
3·2 Narcotics 52-59
Abusable drugs defined as narcotics include many types of compoundssuchasmorphine(Mor),tryptaminesandMDMAs. Amongthese,thecompoundshavingaminogrouporhydroxyl groupwerethesubjectedtoourstudies.Recently,illegaluses ofMDMA(calledecstasy)andMDA(calledlovedrug)bythe young are spreading and causing serious social problems worldwide.Thesedrugsareusedinatabletformandcaneasily be taken orally. This is the most likely reason why these are widely used as recreational drugs among the young. 52 A simultaneous semi-micro column HPLC method with FL detection of MDMA, MDA, MP and AP in rat urine was examined by using DBD-F as a labeling reagent. 53 A semimicrocolumnHPLCcanreducesolventvolumeandsamplesize byminiaturizingthemethod.Thus,itisapplicableforanalysis of expensive chemicals and/or small volumes of biological samples. In this method only a small amount of urine sample (50 mL) was required to determine MDMA and MDA. To evaluate the applicability of the method, MDMA and its metabolite, MDA were monitored after a single administration of MDMA tablets (2.0 mg/kg). DBD-labels could be determined more sensitively by PO-CL detection than by FL detectionasdescribedintheabovesection.MDMA,MDA,MP and AP in hair labeled with DBD-F were determined by an HPLC-PO-CL system combined with a column switching technique. 54 The excess reagent blank peaks on the chromatogram were removed, and then the separation of the labeledcompoundswasachieved.Afterdigestionofhairinan alkali solution, the analytes were extracted with n-heptane and labeled with DBD-F. A mixture of hydrogen peroxide and TCPO in acetonitrile was used as a postcolumn CL reagent. The proposed method was applied to determine MDMA and related compounds in hair samples obtained from patients treated in hospitals ( Table 1 ). The concentration ratio of metabolite to parent compound (e.g.AP/MP or MDA/MDMA) isausefulparametertoindicatetheuseofmetaboliteinaddition totheparentcompound.Aratioofmorethan1suggeststheuse of AP or MDA. Typical chromatograms obtained from hair samples are shown in Fig. 10 . DIB-Cl could be applied as a powerful labeling reagent to determine MDMA and MDA as well as MP and AP as described in the previous paragraph. Furthermore,HPLC-FLmethodstodeterminethesecompounds inblood 55 andhairsamples 56, 57 couldbedeveloped. Additionally, HPLC-FL determination of Mor 58 and pentazocine (PZ) 59 labeled with DIB-Cl were examined. Both medicaments are used as an analgesic for post-operative or cancerpainandarealsoillegallyusedasdrugs.Morinratbrain and blood microdialysates could be directly labeled with no pretreatment.DIB-Morwasseparatedwithin14minwithnmol level of LOD, and the method was successfully applied to the preliminary study of potential pharmacokinetic interaction between Mor and diclofenac (Dic). For reliable PZ determination,cyclazocinewasusedasanIS,andPZandISin plasmaorhairwereextractedbyethylacetate.Thismethodwas appliedtomonitorPZinZuckerrathair(blackandwhite)and plasma samples after administration of 25 mg/kg PZ. As a result, PZ concentration in black hair was about eight-fold higherthanthatinwhitehair.IncorporationratevaluesofPZ (=PZconcentrationinblackorwhitehair/areaunderthecurve (AUC0-inf)ofPZinplasma)were0.053and0.007forblackand whitehair,respectively.
3·3 Obesity drugs 60-64
Obesity drugs such as Fen, Phen and PPA, which can be adulteratedindietproducts,haveaminogroupsintheirchemical structurestoreactwithlabelingreagents.Atfirst,simultaneous determination of dansylated Fen and Phen, in addition to sympathomimeticaminesincludingnorephedrine,ephedrine,2-phenylethylamine and 4-bromo-2,5-dimethoxyphenethylamine wasperformedbyanHPLC-FLmethod. 60 Thelabelswerewell separatedwithin45minwithLODrangingfrom16to255fmol (S/N = 3). The proposed method was applied to the determination of Fen and Phen after an oral administration of these compounds to rats. The analytes labeled with DIB-Cl were also determined by an HPLC-UV method. 61 However, since the sensitivity of these methods was not enough to determine Fen in hair, an HPLC-FL method with DIB-Cl labeling was examined. In this study, Fen and its active metabolite of norfenfluramine (Norf) were measured as target compounds. 62 TheDIB-labelsweremonitoredat430nmwith excitationat325nm.ThemethodwassensitivetoLODof36 pg/mg hair for Fen and to LOD of 16 pg/mg hair for Norf. Furthermore,theavailabilityofFenandNorfasbiomarkersfor N-Fen ingestion was examined. N-Fen, which was also found in diet products, was believed to associate with liver failure. However, sensitive determination of N-Fen is difficult because of its weak UV absorption. Additionally, N-Fen is a tertiary amine and for it to undergo labeling for FL-detection is not feasible. Therefore the proposed method could be applied to determineFenandNorfinhairsamplesobtainedfrompatients whowereondietsandweresuspectedtohaveingestedproducts containingN-Fenandtosufferfromhepatotoxicity.Asaresult, Fen and Norf were detected in patients' hair samples; their typicalchromatogramsareshowninFig. 11 .
PPA has been used as an over-the-counter (OTC) drug, a prescription medicament for cough and cold and an appetite suppressant due to its sympathomimetic activity. Recently, some serious side effects such as hemorrhagic stroke, arrhythmiasandhypertensionwerereported.Forpharmacokinetic studyofPPA,asensitivedeterminationmethodwithHPLC-FL detectionwasdeveloped. 63 PPAinplasma,andbloodandbrain microdialysateswasextractedbyaliquid-liquidextractionwith ethylacetatefollowedbylabelingwithDIB-Cl.TheLODsof PPAinplasmaandbloodandbraindialysateswere17,48and 40 fmol on column, respectively. The method was applied for monitoring of PPA in rat's brain and blood microdialysates administeredwithasingleoraldoseofPPA.
Maz, having no functional group to react with a labeling reagent,isalsoadulteratedindietproducts.Therefore,forMaz determination, hydrolysis of Maz to its metabolite, 2-(2-aminoethyl)-3-(p-chlorophenyl)-3-hydroxyphthalimidine (Met), was performed. This was followed by labeling with DIB-Cl. Maz and Met in plasma and brain were determined by an HPLC-FL method measuring Met after two different sample treatments. 64 TheLODofMetinplasmaandbrainwere2.8and 3.5 fmol at a S/N ratio of 3. The developed method was successfully applied to monitor Maz and Met after a single administrationofMaz(0.5mg/kg).
Advanced Application for Determination of Drugs of Abuse
Indicating applications of the developed methods is very important for researchers who are concerned with analytical chemistrytoavoidfallingintoself-satisfaction.Inthissection the advanced applications based on sensitive determination of abusabledrugsaredescribed.
4·1 Chiral analysis of abusable drugs
65-68
Some medicaments having stereogenic center in their structures are used as racemic mixtures. Chiral separation of medicaments is very important when one enantiomer shows main pharmacological effect and the other shows inactivity, a qualitatively different effect, or severe toxicity. In forensic studies,chiralseparationofdrugsofabusesometimesprovides helpful information. For instance, the S(+)-enantiomer or racemicmixtureofMPismainlyabusedinJapan.Ontheother hand,selegiline,ananti-Parkinson'sdiseaseagentismetabolized inhumanbodyintoR(-)-MP,R(-)-APandtheircorresponding p-hydroxy derivatives. To distinguish patients from abusers, precise determination of enantiomers is required. Thereupon, HPLC-FLmethodsusingDIB-Clforthechiralquantificationof MPandAPinurineandhairweredeveloped. [65] [66] [67] Theenantioseparation of DIB-labels was achieved on a Chiralcel OD-RH column with a mixture of acetonitrile and phosphate-citrate 
4·2 Evaluation of drug-drug interaction potential for abusable drugs
69-72
Drug-drug interaction causes an adverse drug response producedbytheco-exposureofthedrugandanothersubstance, whichmodifiesthepatient'sresponsetosomedrugs.Inforensic cases, abusable drugs might interact with each other by multidrugabuse,andthiscanleadtoserioustoxicsymptoms.Drugdruginteractionsincludepharmacokineticand/orpharmacodynamic interaction. Pharmacokinetic interaction causes the extreme change of free-form (unbound to protein) drugs' concentration in blood and/or target tissue. Consequently, determination of free-formdrugsishelpfultoassessthepharmacokineticinteraction. Manypharmacokineticapproachesofdrug-druginteractionare already well established in the measurements of total drug concentrationratherthanthefree-formdrugandpharmacokinetic parametersinplasma.Somestudieshavefocusedonfree-form drugs in target tissue (e.g. brain and bile). Determination of free-formdrugsintargettissueisexpectedtobeveryusefulto predictmoreparticularinformationaboutinteractions.
Microdialysis has been found to be an important application for in vivo studies of drug pharmacokinetics. This approach makes it possible to sample free-form drugs in extracellular fluidsofessentiallyanytissuebypassivediffusionthroughthe microdialysis probe that consists of a small semi-permeable membrane. In this technique, the typical distribution of freeform drug in target tissue can be estimated with minimal damagetoexperimentalanimals. 69 However,sensitiveanalytical methods are required to determine the analytes because concentrations of the analytes in microdialysates fluids are generallylowandquitesmallsizesofsamplecanbeobtained. In our study, the combination of HPLC separation with fluorescencedetectionusingouroriginallabelingreagent(DIBCl) and microdialysis sampling were used for estimation for drug-druginteractionsofabusabledrugs. 58, [70] [71] [72] MDMAtabletsoftencontainotheractivecomponentshaving hallucinogenic and/or stimulant effect such as caffeine, ketamine,ephedrineormethamphetamine.Afteradministration ofMDMA(5mg/kg,i.p.)withcaffeine(20mg/kg,i.p.)torats, theAUC0-300 of MDMA in blood significantly increased to 1.7 timeshigher(91±5mg minmL -1 ),andtheclearanceofMDMA decreasedbyhalfto51±4mLmin
,suchresultssuggested that caffeine might interfere with renal clearance of MDMA. Ontheotherhand,theCmaxofMDMAandMDA(ametabolite of MDMA) in brain significantly decreased by half (496 ± 80 and 93 ± 21 ng/mL, P < 0.01 and P < 0.05, respectively). Moreover, the Tmax and the mean residence time (MRT) of MDMA and MDA were prolonged (2.1 and 1.3 times, respectively),buttheeliminationhalf-lives(T1/2)ofMDMAand MDA were unchanged. These results showed that caffeine inhibitsthetransportationofMDMAandMDAtobrainviathe blood-brain barrier, although the exclusions of MDMA and MDA from brain to blood were not influenced by caffeine. 70 SuchresultssuggestedthatingredientsinMDMAtabletsmight influencethepharmacokineticsofMDMA,andthisinteraction couldleadabuserstotakehigherdosesofMDMAandtocause poisonouslyhighlevelsofMDMAinblood.
Mor is frequently prescribed in combination with nonsteroidalanti-inflammatorydrugslikeDicforpainrelief.Mor wasalow-transitivecompoundfortheblood-brainbarrier,since theAUCratio(AUCbrain/AUCblood),whichindicatestransitivityof Mortobrain,was0.38afterasingleadministration(10mg/kg, i.p.) to rats. Following co-administration of Mor with Dic (5 mg/kg,i.p.),theAUCbrain/AUCbloodratiowasnotchanged(0.31), and no pharmacokinetic parameters of Mor in either brain or blood were significantly altered. These results suggested that the clinical benefit of combined use of Mor and Dic might be causedbysynergismoftheirdifferentpharmacodynamiceffects and/orbypharmacokineticeffectsofMorglucuronide. 58 Appetite suppressants have been used as Phen-Fen combinations;however,suchusewasfoundtoenhanceweight lossatlowerdosesaswellastheneurotoxiceffect.Theprofiles of pharmacokinetic parameters of Phen in rats, both blood and brain,followingPhen(1or5mg/kg)intheabsenceorpresence ofFen(1or5mg/kg)weresignificantlyaltered.Inratbrains, FensignificantlyincreasedPhenlevels,CmaxandAUCofPhen increased 2.0 -2.2 fold and 3.4 fold (P < 0.05 and P < 0.01, respectively).TheTmaxandMRTofPhenwereprolongedabout 2 times (P < 0.05 respectively), and clearances of Phen were notably decreased by 0.2 -0.3 times (P < 0.05). In blood, similar results were shown, where the AUC of Phen was significantlyincreased(P<0.05).Interestingly,proteinbinding %ofPhen(35%)wasnotalteredbyco-administrationofFen. On the other hand, there was no significant effect on pharmacokineticparametersofeitherFenoritsmetaboliteNorf. These results suggested Fen and/or Norf may have a similar inhibiting effect on the transporters, which is responsible for Phen elimination, thus inhibiting its efflux from brain to the blood.Thiswouldleadtohigherbraindistribution,andhence alteritspharmacokineticparameters.Theconsequenceofsuch alteration in the pharmacokinetics of a CNS drug may play a part in the enhancing effect as well as in the neurotoxicity of PhenandFen. 71 PPA is a synthetic sympathomimetic amine available as a nasaldecongestantandisalsousedasanappetitesuppressantin theUSA.InJapan,PPAwasonlyavailableasadecongestantof OTC products by combination with caffeine and/or chlorphenylamine. Co-administration of caffeine and/or chlorphenylamine significantly affected the pharmacokinetic parametersofPPAinbrains.Combinationsofcaffeine(5mg/kg, i.v.)withPPA(2.5mg/kg,i.p.)causeda1.6-foldincreaseinthe AUCinbraincomparedtosingleadministrationofPPA (Fig.13) , andcombinationofchlorphenylamine(0.4mg/kg,i.v.)causeda 1.8-foldincrease(P<0.05) (Fig.14) .Themultiplecombinations causedanincreaseintheAUCby1.9-fold(P<0.05)similarto that in the AUC of PPA in brain compared to the single administration of the OTC product including PPA, chlorphenylamine,caffeine,belladonnaalkaloidsandlysozyme chloride (2.2-fold, P < 0.05). The Cmax of PPA in brain was significantly increased by co-administration of caffeine, chlorphenylamine or both of them (1.8-, 1.8-and 1.9-fold; P < 0.05, respectively), and the clearance of PPA in brain was significantlydecreasedbyco-administrationofthem(0.6-,0.7-and0.6-fold;P<0.05,respectively).Contrarytotheseresults in brain pharmacokinetics, combined administration did not affect the pharmacokinetics of PPA in blood. InAugust 2002, the manufacturers voluntary removed PPA from OTC products because of the mega-study, which shows an increased risk of hemorrhagestrokerelatedtointakeofPPA.Ourresultsshowed thattheobservedadverseeffectsassociatedwithPPAusecould berelatedtothesignificantincreaseinitslevelsinthebrain. 72 These results revealed the importance of monitoring of pharmacokineticparametersintargettissueinadditiontothese inbloodtoevaluatethepharmacokineticdrug-druginteractions.
Conclusions
Inthisreview,wehavepresentedourresearchresultsobtained overseveralyears.Thesignificantpointscanbesummarizedas follows;
· Synthesis and application of analytical reagents, complying withtherequests · Combination of suitable analytical tools on purpose: especially of luminometric detection and LC separation components · Indication of advanced applicabilities of the developed methods We believe that this research style will be highly helpful for youngresearchersnotonlyscientifically,butalsoeducationally, andwewouldliketocontinuetomakeprogressfromnowon.
